Document is current
Any future updates will be listed below
-
Authors
Rosichini, Marco https://orcid.org/0000-0002-6012-414X
Del Baldo, Giada
De Luca, Carmen Dolores
Benini, Francesca https://orcid.org/0000-0003-2900-6636
Genah, Shirley
Vinci, Maria
Cerimele, Alfredo
Coccetti, Marianna
Flamini, Sara
Carsetti, Rita
Cacchione, Antonella
Carai, Andrea
Mastronuzzi, Angela
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Velardi, Enrico https://orcid.org/0000-0001-8383-0453
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro
Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 4 November 2024
First Online: 20 November 2024
Competing interests
: The authors have no conflict of interest related to this work. Prof. Locatelli reports personal fees from Amgen, personal fees from Novartis, other from Bellicum Pharmaceutical, other from Neovii, personal fees from Miltenyi, personal fees from Medac, personal fees from Jazz Pharmaceutical, personal fees from Takeda, outside the submitted work.
